Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2018

View Archived Issues

Separating graft attacks

BBB fails to slow down prions

Engineered oncolytic virus sticks with glioblastoma

Bayer initiates phase I II study of factor VIII gene transfer therapy with BAY-2599023

TRACON and I-Mab Biopharma enter immuno-oncology partnership

Identification of the PANK activator PZ-2891 for pantothenate kinase-associated neurodegeneration

Zogenix presents phase III data for fenfluramine in children and young adults with Dravet syndrome

First patient dosed in alloSHRINK phase I study of CYAD-101

Salivary RNA test developed for diagnosing childhood autism spectrum disorder

Bristol-Myers Squibb patents IRAK-4 inhibitors

Enanta Pharmaceuticals discloses MAP3K5 inhibitors

CD73 inhibitors reported in Eternity Bioscience patent

FDA clears IND application to initiate phase I/II study of KRAS G12C inhibitor, MRTX-849

ORIC Pharmaceuticals synthesizes CD73 inhibitors

Guangzhou Wellhealth Bio-Pharmaceutical divulges PARP-1 inhibitors

First subject successfully enrolled in first-in-human study of AT-1501 as treatment for ALS

Targeting the chromatin assembly factor complex blocks leukemia development in mice

Pain Therapeutics begins phase IIa study of PTI-125 in mild to moderate Alzheimer's disease

Bayer presents first phase I data for BAY-1093884 in patients with hemophilia

Leo Pharma initiates phase IIb studies of delgocitinib for atopic dermatitis and chronic hand eczema

ASH 2018: CRISPR screening gives clues to drug sensitivities of rare AML subtype

Biohaven reports topline data from phase III study of Zydis ODT rimegepant for acute migraine

Researchers present data for S-63845 in B-cell precursor ALL

Sienna reports phase IIb topline data on SNA-120 in psoriasis

Phase III ERADICATE Hp2 study of Talicia meets primary endpoint of H. pylori eradication

FDA approves Dextenza intracanalicular insert to treat postsurgical ocular pain

New phase II investigator-initiated study evaluates nitazoxanide in NASH-induced fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...